{"id":3700,"date":"2024-10-10T08:17:26","date_gmt":"2024-10-10T05:17:26","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3700"},"modified":"2024-10-10T08:18:14","modified_gmt":"2024-10-10T05:18:14","slug":"erken-teshis-ve-tedavi-kalp-hastaliklarindan-korunmada-hayati-oneme-sahip","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3700","title":{"rendered":"\u00a0Erken Te\u015fhis ve Tedavi Kalp Hastal\u0131klar\u0131ndan Korunmada Hayati \u00d6neme Sahip!"},"content":{"rendered":"\n

Novartis T\u00fcrkiye ve T\u00fcrk Kardiyoloji Derne\u011fi (TKD), D\u00fcnya Kalp G\u00fcn\u00fc\u2019n\u00fc kutlamak ve kalp sa\u011fl\u0131\u011f\u0131 konusunda toplumda fark\u0131ndal\u0131k yaratmak amac\u0131yla, kalp sa\u011fl\u0131\u011f\u0131 ve dislipidemi \u00fczerine yo\u011funla\u015fan bir bilin\u00e7lendirme projesi ba\u015flatt\u0131.Proje kapsam\u0131nda bas\u0131n ve sosyal medya arac\u0131l\u0131\u011f\u0131yla toplumu kalp sa\u011fl\u0131\u011f\u0131 hakk\u0131nda bilgilendirerek, kalp hastal\u0131klar\u0131n\u0131n \u00f6nlenmesi ve tedavisi konusundaki \u00f6nemli mesajlar\u0131n geni\u015f kitlelere ula\u015ft\u0131r\u0131l\u0131lmas\u0131 hedefleniyor.<\/strong><\/p>\n\n\n\n

Kalp hastal\u0131klar\u0131, d\u00fcnya genelinde en yayg\u0131n \u00f6l\u00fcm nedenlerinden biri. D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc verilerine g\u00f6re, her y\u0131l yakla\u015f\u0131k 18 milyon insan kalp hastal\u0131klar\u0131 nedeniyle hayat\u0131n\u0131 kaybediyor. Bu rakamlar, kalp sa\u011fl\u0131\u011f\u0131n\u0131n korunmas\u0131n\u0131n ne denli kritik oldu\u011funu g\u00f6zler \u00f6n\u00fcne seriyor.<\/p>\n\n\n\n

T\u00fcrkiye \u0130statistik Kurumunun (T\u00dc\u0130K) \u00f6l\u00fcm verileri toplam \u00f6l\u00fcmlerin i\u00e7inde kalp hastal\u0131klar\u0131n\u0131n pay\u0131n\u0131n gittik\u00e7e artma e\u011filiminde oldu\u011funu g\u00f6steriyor. Kalp hastal\u0131klar\u0131 1989\u2019da y\u00fczde 40, 1993\u2019te y\u00fczde 45,2009\u2019da y\u00fczde 40 ve 2013\u2019te y\u00fczde 39.6, 2014 y\u0131l\u0131nda y\u00fczde 40,4 ile t\u00fcm \u00f6l\u00fcm nedenleri aras\u0131nda ilk s\u0131rada yer al\u0131yor.<\/p>\n\n\n\n

T\u00fcrkiye\u2019de kalp sa\u011fl\u0131\u011f\u0131 ve dislipidemi<\/strong><\/p>\n\n\n\n

T\u00fcrkiye\u2019de her y\u0131l binlerce insan kalp ve damar hastal\u0131klar\u0131na ba\u011fl\u0131 nedenlerle ya\u015fam\u0131n\u0131 yitiriyor. Bu hastal\u0131klar\u0131n \u00f6nemli bir nedeni olarak dislipidemi \u00f6ne \u00e7\u0131k\u0131yor. Dislipidemi, kanda anormal seviyelerde lipid bulunmas\u0131 durumu olarak tan\u0131mlan\u0131yor ve \u00f6zellikle y\u00fcksek LDL (k\u00f6t\u00fc kolesterol) seviyeleri ile d\u00fc\u015f\u00fck HDL (iyi kolesterol) seviyeleri kalp hastal\u0131klar\u0131na zemin haz\u0131rlayabiliyor. Dislipidemi, ateroskleroz geli\u015fimine yol a\u00e7arak kalp krizi ve inme riskini art\u0131r\u0131yor.<\/p>\n\n\n\n

Genel olarak iskemik kalp hastal\u0131klar\u0131n\u0131n 1\/3\u2019\u00fcn\u00fcn y\u00fcksek kolesterolle ili\u015fkili oldu\u011fu belirtiliyor. T\u00fcm d\u00fcnyada y\u0131lda 2,6 milyon \u00f6l\u00fcm\u00fcn (y\u00fczde 4,5) ve 29,7 milyon DALY (Engellili\u011fe g\u00f6re ayarlanm\u0131\u015f ya\u015fam y\u0131llar\u0131) veya total DALY\u2019nin y\u00fczde 2\u2019sinin y\u00fcksek kolesterole ba\u011fl\u0131 oldu\u011fu tahmin ediliyor ve y\u00fcksek serum kolesterol\u00fcn\u00fc d\u00fc\u015f\u00fcrmenin kalp hastal\u0131\u011f\u0131 riskini azalt\u0131yor.<\/p>\n\n\n\n

Y\u00fcksek LDL kolesterol seviyeleri, damar t\u0131kan\u0131kl\u0131klar\u0131na ve kalp krizlerine yol a\u00e7\u0131yor<\/strong><\/p>\n\n\n\n

T\u00fcrk Kardiyoloji Derne\u011fi Ba\u015fkan\u0131 Prof. Dr. Muzaffer De\u011fertekin, T\u00fcrkiye\u2019de dislipidemi fark\u0131ndal\u0131\u011f\u0131n\u0131n yeterli d\u00fczeyde olmad\u0131\u011f\u0131n\u0131 belirterek, bu konuda toplumun daha fazla bilgilendirilmesi gerekti\u011fine dikkat \u00e7ekti. \u201cDislipidemi, halk aras\u0131nda yeterince tan\u0131nm\u0131yor ve bu durum ciddi sa\u011fl\u0131k sorunlar\u0131na yol a\u00e7abiliyor. Kanda y\u00fcksek LDL kolesterol seviyeleri, damar t\u0131kan\u0131kl\u0131klar\u0131na ve bunun sonucunda kalp krizlerine yol a\u00e7abilir. Erken te\u015fhis ve tedavi, kalp hastal\u0131klar\u0131ndan korunmada hayati \u00f6neme sahip\u201d diyen Prof. Dr. De\u011fertekin, bu ba\u011flamda e\u011fitim ve bilin\u00e7lendirme \u00e7al\u0131\u015fmalar\u0131n\u0131n art\u0131r\u0131lmas\u0131 gerekti\u011fini vurgulad\u0131. Ayr\u0131ca, dislipideminin neden oldu\u011fu kalp hastal\u0131klar\u0131n\u0131n belirtileri genellikle sessizce ilerledi\u011fi i\u00e7in d\u00fczenli sa\u011fl\u0131k kontrollerinin \u00f6nemi \u00fczerinde durdu.<\/p>\n\n\n\n

Erken te\u015fhisin ve tedavi se\u00e7eneklerinin \u00f6nemi<\/strong><\/p>\n\n\n\n

Kalp hastal\u0131klar\u0131n\u0131n belirtileri genellikle ge\u00e7 fark edilse de erken te\u015fhis ile bu hastal\u0131klar\u0131n \u00f6nlenmesinin m\u00fcmk\u00fcn oldu\u011funu belirten Prof. Dr. De\u011fertekin, \u00f6zellikle yenilik\u00e7i tedavi se\u00e7eneklerinin kalp sa\u011fl\u0131\u011f\u0131n\u0131n korunmas\u0131nda \u00f6nemli rol oynad\u0131\u011f\u0131n\u0131 kaydetti. Bu ba\u011flamda, geli\u015ftirilen yenilik\u00e7i tedavi y\u00f6ntemlerinin, kalp sa\u011fl\u0131\u011f\u0131n\u0131n korunmas\u0131 ve hastal\u0131klar\u0131n \u00f6nlenmesinde b\u00fcy\u00fck bir ad\u0131m oldu\u011funu s\u00f6yleyen Prof. De\u011fertekin \u201cStatinler, PCSK9 inhibit\u00f6rleri gibi tedaviler, dislipidemi y\u00f6netiminde \u00f6nemli yer tutuyor ve kalp krizi riskini \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131yor\u201d dedi.<\/p>\n\n\n\n

Novartis kalp hastal\u0131klar\u0131 alan\u0131nda yenilik\u00e7i tedaviler geli\u015ftirmeye devam ediyor<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Novartis T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Natacha Theytaz, Novartis\u2019in kalp sa\u011fl\u0131\u011f\u0131 alan\u0131nda d\u00fcnya genelinde k\u00f6kl\u00fc bir ge\u00e7mi\u015fe sahip oldu\u011funu belirtti. \u201cNovartis, son altm\u0131\u015f y\u0131ld\u0131r, kardiyovask\u00fcler hastal\u0131klar i\u00e7in bak\u0131m standard\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrmekten d\u00fc\u015f\u00fck gelirli toplumlardaki sa\u011fl\u0131k sistemlerini g\u00fc\u00e7lendirmeye kadar d\u00fcnya \u00e7ap\u0131nda kalp sa\u011fl\u0131\u011f\u0131n\u0131 geli\u015ftirmek i\u00e7in \u00e7al\u0131\u015f\u0131yor\u201d diyen Theytaz, kalp-damar hastal\u0131klar\u0131na ba\u011fl\u0131 \u00f6l\u00fcmlerinin y\u00fczde 85’inden fazlas\u0131n\u0131 aterosklerotik kardiyovask\u00fcler hastal\u0131klar\u0131n olu\u015fturdu\u011funu ifade etti ve \u015f\u00f6yle devam etti: \u201cBurada ana risk fakt\u00f6r\u00fc, \u2018k\u00f6t\u00fc kolesterol\u2019 olarak da adland\u0131r\u0131lan y\u00fcksek LDL-C’dir (d\u00fc\u015f\u00fck yo\u011funluklu lipoprotein kolesterol). Statinler \u015fu anda d\u00fcnya \u00e7ap\u0131nda ASCVD hastalar\u0131n\u0131n y\u00fczde 90’\u0131na LDL-C’yi d\u00fc\u015f\u00fcrmek i\u00e7in re\u00e7ete edilmektedir, ancak bunlar\u0131n y\u00fczde 70’inden fazlas\u0131 optimal LDL-C seviyesinde de\u011fildir ve kardiyovask\u00fcler olay ve \u00f6l\u00fcm risklerini art\u0131rmaktad\u0131r. KVH ile m\u00fccadele taahh\u00fcd\u00fcm\u00fcz\u00fcn bir par\u00e7as\u0131 olarak, kalbin v\u00fccudun ihtiya\u00e7lar\u0131n\u0131 kar\u015f\u0131lamak i\u00e7in yeterince kan pompalayamad\u0131\u011f\u0131 potansiyel olarak ya\u015fam\u0131 tehdit eden bir durum olan kalp yetmezli\u011fine de odaklan\u0131yoruz. Bu durum hastalar\u0131n yorgun ve nefes darl\u0131\u011f\u0131 hissetmesine yol a\u00e7\u0131yor ve hastaneye yatma veya ani kalp \u00f6l\u00fcm\u00fc riski ta\u015f\u0131yor. D\u00fcnya genelinde en az 26 milyon ki\u015fi kalp yetmezli\u011fi ile ya\u015f\u0131yor. Bu da, k\u00fcresel ekonomiye her y\u0131l hem do\u011frudan hem de dolayl\u0131 maliyetler a\u00e7\u0131s\u0131ndan tahmini 108 milyar ABD dolar\u0131 tutar\u0131nda b\u00fcy\u00fck bir y\u00fck olu\u015ftu\u011funu g\u00f6steriyor.\u201d<\/p>\n\n\n\n

Theytaz s\u00f6zlerini bitirirken bu alanda \u00f6nc\u00fc olduklar\u0131n\u0131 ve hastalar\u0131n ilaca eri\u015fimini kolayla\u015ft\u0131rmak i\u00e7in hekimlerle i\u015f birli\u011fi i\u00e7inde \u00e7al\u0131\u015ft\u0131klar\u0131n\u0131 da ifade etti.<\/p>\n","protected":false},"excerpt":{"rendered":"

Novartis T\u00fcrkiye ve T\u00fcrk Kardiyoloji Derne\u011fi (TKD), D\u00fcnya Kalp G\u00fcn\u00fc\u2019n\u00fc kutlamak ve kalp sa\u011fl\u0131\u011f\u0131 konusunda toplumda fark\u0131ndal\u0131k yaratmak amac\u0131yla, kalp sa\u011fl\u0131\u011f\u0131 ve dislipidemi \u00fczerine yo\u011funla\u015fan bir bilin\u00e7lendirme projesi ba\u015flatt\u0131.Proje kapsam\u0131nda bas\u0131n ve sosyal medya arac\u0131l\u0131\u011f\u0131yla toplumu kalp sa\u011fl\u0131\u011f\u0131 hakk\u0131nda bilgilendirerek, kalp hastal\u0131klar\u0131n\u0131n \u00f6nlenmesi ve tedavisi konusundaki \u00f6nemli mesajlar\u0131n geni\u015f kitlelere ula\u015ft\u0131r\u0131l\u0131lmas\u0131 hedefleniyor.<\/p>\n","protected":false},"author":1,"featured_media":3702,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3700"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3700"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3700\/revisions"}],"predecessor-version":[{"id":3704,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3700\/revisions\/3704"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3702"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}